Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma
NCT05236036Phase 1Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Aug 2022
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mycophenolate mofetil in glioblastoma (GBM) (5 arms), sponsored by Northwestern University. Primary endpoint: Maximum tolerated dose/recommended phase 2 dose. Started Aug 2022; status: active, not recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05236036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236036.